A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0426
Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N014A
Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma Ansell, Stephen M. , Inwards, David J. , Rowland, Kendrith M. ... - - Cancer - 2008 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N0186
Cancer and Leukemia Group B studies of recombinant Interleukin-2 maintenance therapy in acute myeloid leukemia Baer, M. R. , Kolitz, J. E. , George, S. L. , Caligiuri, M. A. ... - - Ann Hematol - 2008 Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - CALGB-19808
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720 , CALGB-9760
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8525 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9 Barton, D. L. , Lavasseur, B. , Sloan, J. A. , Stella, P. J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Symptom Inter - N05C9
Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502 Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502
Interruptions Of Once-Daily Thoracic Radiotherapy Do Not Correlate With Outcomes In Limited Stage Small Cell Lung Cancer: Analysis of CALGB Phase III Trial 9235 Bogart, Jeffrey A. , Watson, Dorothy , McClay, Edward F. ... - - Lung Cancer - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-9235
A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM) Brown, P. D. , Krishnan, S. , Sarkaria, J. , Wu, W. , Mischel, P. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0177
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177 Brown, Paul D. , Krishnan, Sunil , Sarkaria, Jann N. , Wu, Wenting ... - - J Clin Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0177
What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings Campbell, M. E. , Mandrekar, S. J. , Hillman, S. L. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N0026 , NCCTG-N9741
Association of Family History with Cancer Recurrence and Survival Among Patients with Stage III Colon Cancer Chan, Jennifer A. , Meyerhardt, Jeffrey A. , Niedzwiecki, Donna ... - - JAMA - 2008 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - C89803
A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402 Czuczman, M. S. , Johnson, J. L. , Jung, S. ... - - Ann. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50402
FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R] Czuczman, M. S. , Leonard, J. P. , Johnson, J. L. , Jung, S.-H. ... - - Blood - 2008 Abstract - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50402
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study D'Amico, Anthony V. , Halabi, Susan , Tempany, Clare ... - - Int J Radiat Oncol Biol Phys - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GU - CALGB-9682
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). D'Amico, Anthony V , Halabi, Susan , Vollmer, Robin ... - - Urology - 2008 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-159807 , CALGB-9682
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Dawson, Nancy A , Halabi, Susan , Ou, San-San , Biggs, David D ... - - Clin Genitourin Cancer - 2008 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-90004
Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (REC) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated findings from the 20,800 patient (Pt) ACCENT dataset De Gramont, A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - N0441
Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000 Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9000
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. DiGiovanna, Michael P , Stern, David F , Edgerton, Susan ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - C8541
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. Edelman, Martin J , Watson, Dee , Wang, Xiaofei , Morrison, Carl ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30203
Factors contributing to cancer screening in African Americans Ferrans, C. E. , Ryan, C. , Archer, L. E. , Freels, S. , Lan, L. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-119901
Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation. Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424
Prognostic Significance of Defective Mismatch Repair and BRAF-V600E in Patients with Colon Cancer French, Amy J. , Sargent, Daniel J. , Burgart, Lawrence J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GI - NCCTG-98-46-54
Dietary and lifestyle determinants of colon cancer recurrence and survival Fuchs, C. S. , Meyerhardt, J. A. , Ng, K. , Niedzwiecki, D. ... - NCI TSM - - 2008 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - GI - C89803
Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741 Fuchs, Charles S. , Goldberg, Richard M. , Sargent, Daniel J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GI - N9741
Vorinostat in glioblastoma multiforme (Gbm): updated results from phase I and II trials provide the rationale for further clinical development. Galanis, E. , Jaeckle, K. , Buckner, J. , Maurer, M. , Hardwick, J. ... - - Ann. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N047B
Role of SULT1A1 copy number in tamoxifen treated breast cancer: findings from the North Central Cancer Treatment Group (NCCTG) adjuvant trial 89-30-52. Goetz, M. P. , Moyer, A. M. , Weinshilboum, R. M. , Suman, V. A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - PPP - NCCTG-89-30-52
CYP2D6 and HOXB13/IL17BR: Combining inherited and tumor gene markers for prediction of tamoxifen resistance Goetz, Matthew P. , Suman, Vera J. , Couch, Fergus J. ... - - Clin Cancer Res - 2008 Manuscript - Secondary Endpoint - Primary Analysis - PPP - NCCTG-89-30-52
A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non small cell lung cancer: CALGB 30407 early evaluation of feasibility and toxicity Govindan, R. , Bogart, J. A. , Wang, X. , Liu, D. , Kratzke, R. A. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - CALGB-30407
Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. Graziano, Stephen L , Herndon, James E , Socinski, Mark A ... - - J Thorac Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39901
Local excision of distal rectal cancer: An update of Cancer and Leukemia Group B 8984 Greenberg, J. A. , Shibata, D. , Herndon, J. E. 2nd ... - - Am Soc Colon Rectal Surg - 2008 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - C8984
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Greenberg, Jacob A , Shibata, David , Herndon, James E ... - - Dis. Colon Rectum - 2008 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - C8984
Baseline quality of life (QOL) is a strong and performance status (PS)-independent prognostic factor for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) Grothey, A. , Sargent, D. J. , Szydlo, W. , Zhao, X. , Campbell, M. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. Grothey, Axel , Hedrick, Eric E , Mass, Robert D , Sarkar, Somnath ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9741
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Hackanson, Björn , Bennett, Kristi L , Brena, Romulo M ... - - Cancer Res. - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9665
Is progression free survival a predictor of overall survival in men with castration recurrent prostate cancer (CRPC)? Halabi, S. , Ou, S. , Vogelzang, N. J. ... - ASCO GU - - 2008 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GU - C9181 , C9182 , CALGB-90004 , CALGB-90006 , CALGB-9583 , CALGB-9680 , CALGB-9780 , CALGB-99813 , INT-0159
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. Halabi, Susan , Vogelzang, Nicholas J , Kornblith, Alice B ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GU - Comprehensive
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group Heinrich, Michael C. , Owzar, Kouros , Corless, Christopher L. ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - PPP - CALGB-150105
Patient Education Level As a Predictor of Survival In Lung Cancer Clinical Trials Herndon, James E. , Kornblith, Alice B. , Holland, Jimmie C. ... - - J Clin Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-70601
N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy Hobday, T. J. , Stella, P. J. , Fitch, T. R. , Jaslowski, A. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0436
A North Central Cancer Treatment Group (NCCTG) Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline and/or a Taxane. Hobday, T. , Rowland, K., Jr , Dueck, A. , Northfelt, D. , Lingle, W. ... - ASCO Breast - Breast Cancer Symposium - 2008 Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0537
Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial Holtan, S. G. , Foster, N. R. , Erlichman, C. E. , Aubry, M. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N004E
Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study Hsi, E. D. , Said, J. , Johnson, J. L. , Jung, S. , Lai, R. , Jones, D. ... - ASH - Blood - 2008 Abstract - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-50103
Ki67 and PIM1 expression in aggressively treated mantle cell lymphoma (MCL): A Cancer and Leukemia Group B (CALGB) 59909 correlative science study Hsi, E. , Jung, S. , Lai, R. , Johnson, J. , Cook, J. , Jones, D. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Lymphoma - CALGB-59909
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study Hsi, Eric D. , Jung, Sin-Ho , Lai, Raymond , Johnson, Jeffrey L. ... - - Leuk. Lymphoma - 2008 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Lymphoma - CALGB-59909
Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Hurwitz, Mark D , Halabi, Susan , Ou, San-San , McGinnis, Lamar S ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2008 Manuscript - Primary Endpoint - Preliminary Analysis - GU - CALGB-99809
MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: Preliminary Findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657 Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - RSNA - Radiological Society of North America 94th Scientific Assembly and Annual Meeting - 2008 Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-150007
Long-term Results of the Treatment of Patients With Mantle Cell Lymphoma With Cladribine (2-CDA) Alone (95-80-53) or 2-CDA and Rituximab (N0189) in the North Central Cancer Treatment Group Inwards, David J. , Fishkin, Paul A. S. , Hillman, David W. ... - - Cancer - 2008 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Lymphoma - N0189 , NCCTG-95-80-53
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803 Jackson, N. A. , Fuchs, C. S. , Niedzwiecki, D. , Hollis, D. R. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - C89803
Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials Jaeckle, K. A. , Wu, W. , Kosel, M. , Flynn, P. J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N047D
Phase I/II trial of sorafenib and CCI-779 in patients with recurrent glioblastoma (GBM) Jaeckle, K. , Anderson, K. , Sarkaria, J. , Decker, P. , Buckner, J. ... - ICTT - - 2008 Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - NCCTG-N0572
Elderly patients with metastatic esophageal/gastric cancer: a pooled analysis of age-based outcomes from 8 consecutive North Central Cancer Treatment Group (NCCTG) therapeutic trials Jatoi, A. , Foster, N. R. , Egner, J. , Burch, P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - N064C
Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)1 Jatoi, Aminah , Dakhil, Shaker R. , Foster, Nathan R. , Ma, Cynthia ... - - J Thorac Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - GI - N044B
Tetracycline to Prevent Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rashes: Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N03CB)1 Jatoi, Aminah , Rowland, Kendrith , Sloan, Jeff A. , Gross, Howard M. ... - - Cancer - 2008 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N03CB
Phase II trial of pemetrexed (P) and carboplatin (C) in previously untreated extensive stage disease small cell lung cancer (ED-SCLC): A NCCTG Study Jett, J. R. , Bernath, A. Jr , Foster, N. , Molina, J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0423
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Johnson, Elizabeth A , Marks, Randolph S , Mandrekar, Sumithra J ... - - Lung Cancer - 2008 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-972451
Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E Katipamula, Rajini , Jatoi, Aminah , Foster, Nathan R. ... - - Clin Med Oncol - 2008 Manuscript - Secondary Endpoint - Preliminary Analysis - GI - N044E
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Kelly, William Kevin , Halabi, Susan , Elfiky, Aymen , Ou, San-San ... - - Cancer - 2008 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-99811
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU) and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. G. , Foster, N. , Bollinger, J. , Stella, P. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-N0349
Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemicitabine (GEM) in patients with unresectable pancreatic cancer Kim, G. P. , Haddock, M. , Foster, N. R. , Bollinger, J. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GI - N0349
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. Korn, Edward L , Liu, Ping-Yu , Lee, Sandra J ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N9975
Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results Kostakoglu, L. , Straus, D. J. , Schoder, H. , Lacasce, A. S. ... - ASH - ASH Annual Meeting Abstracts - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Lymphoma - CALGB-50203
A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E. Kottschade, L. , Suman, V. , Amatruda, T. , Mcwilliams, R. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Preliminary Analysis - Experimental - N057E
Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer? Kozower, Benjamin D , Meyers, Bryan F , Reed, Carolyn E ... - - Ann. Thorac. Surg. - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0050
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. Kratzke, Robert A , Wang, Xiaofei , Wong, Long , Kratzke, Marian G ... - - J Thorac Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-159904
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Lai, Raymond , Bartlett, Nancy L , Mackey, John R , Jung, Sin-Ho ... - - Leuk. Lymphoma - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Correl Sci NOS - CALGB-59804
Differences in clinical trial patient attributes and outcomes according to trial enrollment setting: Analyses from 10 CALGB lung cancer trials Lamont, E. B. , Archer, L. E. , Lan, L. , Vokes, E. E. , Mcneil, B. J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Disparities - CALGB-70602
Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants Lamont, Elizabeth B. , Herndon, James E. , Weeks, Jane C. ... - - Med Care - 2008 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - CALGB-70101
Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study Langer, C. , Maharry, K. S. , Mrozek, K. A. , Paschka, P. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-9621
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study Langer, Christian , Radmacher, Michael D. , Ruppert, Amy S. ... - - Blood - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
What Determines the Outcome for Adolescents and Young Adults With Acute Lymphoblastic Leukemia? Larson, R. A. ... - - Ann Hematol - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - C8811 , C9331 , CALGB-19802 , CALGB-8461
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome Ley, T. J. , Mardis, E. R. , Ding, L. , Fulton, B. , Mclellan, M. D. ... - - Nature - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C9665 , C8461
Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: A pooled analysis of 2,440 patients (pts) Liu, H. , Tan, A. D. , Grothey, A. , Schaefer, P. L. , Buckner, J. C. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Symptom Inter - Comprehensive
Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel Liu, Minetta C. , Demetri, George D. , Berry, Donald A. ... - - Cancer Treat Rev - 2008 Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Breast - C9141
Are actual tumor measurements or categorical tumor response status better at predicting overall survival in cancer clinical trials? Mandrekar, M. D. , Hillman, S. L. , Campbell, M. E. , Hobbs, B. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9741
Comparison of progression-free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): A North Central Cancer Treatment Group (NCCTG) investigation Mandrekar, S. J. , Hillman, S. L. , Ziegler, K. L. Allen ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424
Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study Marcucci, Guido , Maharry, Kati , Radmacher, Michael D. ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
MicroRNA expression in cytogenetically normal acute myeloid leukemia. Marcucci, Guido , Radmacher, Michael D , Maharry, Kati ... - - N. Engl. J. Med. - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG study1 Markovic, Svetomir N. , Suman, Vera J. , Nevala, Wendy K. ... - - Am J Clin Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N0071
Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA Martenson, James A. , Halyard, Michele Y. , Sloan, Jeff A. ... - - J Clin Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - Symptom Inter - N00CA
Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203 Mcleod, H. L. , Owzar, K. , Kroetz, D. L. , Innocenti, F. , Das, S. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - PPP - CALGB-80203
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB 9281). Meropol, Neal J , Niedzwiecki, Donna , Shank, Brenda ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-9281
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia Metzeler, Klaus H. , Hummel, Manuela , Bloomfield, Clara D. ... - - Blood - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-8461 , CALGB-9621 , CALGB-9665
Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803 Meyerhardt, Jeffrey A. , Niedzwiecki, Donna , Hollis, Donna ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803
A phase II study of epratuzumab and rituximab in combination with cyclophsophamide, doxorubicin, vincrisine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma Micallef, I. N. , Maurer, M. J. , Nikcevich, D. A. , Cannon, M. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - N0489
Promising results of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. Micallef, I. N. , Maurer, M. , Nikcevich, D. , Cannon, M. , Moore, D. ... - - Ann. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0489
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). Miller, Antonius A , Wang, Xiaofei F , Gu, Lin , Hoffman, Philip ... - - J Thorac Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30303
Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2 + BC): Results from the NCCTG adjuvant intergroup trial N9831 Moreno-Aspitia, A. , Dueck, A. , Lingle, W. , Kutteh, L. , Tenner, K. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience Mrózek, Krzysztof , Carroll, Andrew J. , Maharry, Kati ... - - Int. J. Oncol. - 2008 Manuscript - No-Endpoint Endpoint - Comprehensive Analysis - Leuk Corr Sci - CALGB-8461
Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907 Muss, H. B. , Berry, D. A. , Cirrincione, C. T. , Theodoulou, M. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Older Adult - CALGB-49907
Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study Neubauer, Andreas , Maharry, Kati , Mrózek, Krzysztof ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - C8525 , C8765 , CALGB-8461 , CALGB-9665
Phase II trial of polyglutamated paclitaxel (PPX) with capecitabine for metastatic breast cancer Northfelt, D. , Allred, J. , Liu, H. , Hobday, T. , Rodacker, M. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Breast - N0437
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603 O'Reilly, E. M. , Gilman-Rosen, L. F. , Niedzwiecki, D. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80603
LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin CALGB 80402 Ocean, A. J. , Niedzwiecki, D. , Atkins, J. N. , Parker, B. A. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80402
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. Okuno, Scott H , Delaune, Robert , Sloan, Jeff A , Foster, Nathan R ... - - Cancer - 2008 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0021
Arm/Hand Swelling and Perceived Functioning among Breast Cancer Survivors 12 Years Post-diagnosis: CALGB 79804 Oliveri, Jill M. , Day, Jeannette M. , Alfano, Catherine M. ... - - J Cancer Surviv - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Health Outcome - CALGB-79804
Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. Olson, John A , McCall, Linda M , Beitsch, Peter , Whitworth, Pat W ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z0010 , ACOSOG-Z0011
Dietary modification in patients with prostate cancer on active surveillance: a randomized, multicentre feasibility study. Parsons, J Kellogg , Newman, Vicky A , Mohler, James L ... - - BJU Int. - 2008 Manuscript - Primary Endpoint - Primary Analysis - Prevention - Comprehensive
The Men's Eating and Living (MEAL) study: a Cancer and Leukemia Group B pilot trial of dietary intervention for the treatment of prostate cancer. Parsons, J Kellogg , Newman, Vicky , Mohler, James L , Pierce, John P ... - - Urology - 2008 Manuscript - Primary Endpoint - Primary Analysis - Prevention - Comprehensive
CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907 Partridge, A. H. , Archer, L. E. , Kornblith, A. B. , Gralow, J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Experimental - C60104
Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study Paschka, Peter , Marcucci, Guido , Ruppert, Amy S. ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
Applying a Conceptual Model for Examining Health-Related Quality of Life in Long-Term Breast Cancer Survivors: CALGB Study 79804 Paskett, Electra D. , Herndon, James E. , Day, Jeannette M. ... - - Psychooncology - 2008 Manuscript - Primary Endpoint - Primary Analysis - Health Outcome - C8541 , CALGB-79804
Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon Picozzi, V. J. , Abrams, R. A. , Traverso, L. W. , O'Reilly, E. M. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z05031
Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840—Cancer and Leukemia Group B Polite, Blase N. , Cirrincione, Constance , Fleming, Gini F. ... - - J. Clin. Oncol. - 2008 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - CALGB-40501 , CALGB-9342 , CALGB-9840
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Posner, Mitchell C , Niedzwiecki, Donna , Venook, Alan P ... - - Ann. Surg. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-89903
Activated EGFR as a prognostic marker in human colon cancer Rego, R. L. , Smyrk, T. C. , Foster, N. R. , Sargent, D. J. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0442
Prognostic value of Class III B-Tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin based chemotherapy (CT): A validation study on 3 randomized trials Reiman, T. , Seve, P. , Vataire, A. , Dunant, A. , Rosell, R. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-150802
The concordance between NCCTGs and NSABPs C-myc FISH assays Reinholz, M. , Dueck, A. , Lingle, W. , Ziegler, A. , Wiktor, A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Correl Sci NOS - N9831
CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma Rini, B. I. , Halabi, S. , Rosenberg, J. E. , Stadler, W. M. ... - ASCO GU - Genitourinary Cancers Symposium - 2008 Abstract - Primary Endpoint - Preliminary Analysis - GU - CALGB-90206
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 Rini, Brian I. , Halabi, Susan , Rosenberg, Jonathan E. ... - - J Clin Oncol - 2008 Manuscript - Primary Endpoint - Preliminary Analysis - GU - CALGB-90206
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207 Rosenberg, J. E. , Halabi, S. , Sanford, B. L. , Himelstein, A. L. ... - - Ann. Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-90207
N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer Roy, V. , Pockaj, B. , Northfelt, D. , Allred, J. , Liu, H. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Breast - N0338
Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103 Rudin, Charles M. , Salgia, Ravi , Wang, Xiaofei , Hodgson, Lydia D. ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30103
Risk stratified analysis improves prediction of treatment (Rx) benefit over subgroup analysis: Findings from Intergroup N9741 Sanoff, H. K. , Campbell, M. E. , Pitot, H. C. , Goldberg, R. M. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741 Sanoff, Hanna K. , Sargent, Daniel J. , Campbell, Megan E. ... - - J Clin Oncol - 2008 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - N9741
Overall and 12 week tumor response versus actual tumor measurements as predictors of overall survival (OS) in advanced colorectal cancer (ACRC): Findings from NCCTG N9741. Sargent, D. J. , Campbell, M. E. , Grothey, A. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Baseline quality of life (QOL) as a prognostic factor for overall survival (OS) in patients (Pts) with advanced stage non-small cell lung cancer (A-NSCLC): An analysis of NCCTG studies. Schild, S. E. , Qi, Y. , Tan, A. D. , Mandrekar, S. J. , Adjei, A. A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - NCCTG-N0424
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. Seidman, Andrew D , Berry, Donald , Cirrincione, Constance ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9840
Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809 Shapiro, C. L. , Halabi, S. , Gibson, G. , Friedlander, R. J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Preliminary Analysis - Symptom Inter - CALGB-79809
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study Shedden, K. , Taylor, J. M. , Enkemann, S. A. , Tsao, M. S. ... - - Nat. Med. - 2008 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - C9761 , C150302 , CALGB-9761
Association of reduced intraepithelial CD3+/regulatory T-cell ratio with poor outcome in human colon cancers Sinicrope, F. A. , Rego, R. L. , Foster, N. R. , Sargent, D. J. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0442
Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas Sinicrope, Frank A. , Rego, Rafaela L. , Okumura, Kenji ... - - Clin Cancer Res - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0442
Tumor burden is not related to quality of life in patients with metastatic colorectal cancer Sloan, J. , Grothey, A. , Green, E. , Zhao, X. , Campbell, M. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Smith, Sonali M , Grinblatt, David , Johnson, Jeffrey L ... - - Br. J. Haematol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50002
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. Socinski, Mark A , Blackstock, A William , Bogart, Jeffrey A ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30105
Management of recurrent prostate cancer after radiotherapy: Results from CALGB 9687, a contemporary prospective multi-institutional salvage radical prostatectomy series Sokoloff, M. H. , Steinberg, G. D. , Halabi, S. , Sanford, B. L. ... - AUA - J Urol - 2008 Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-9687
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B trial 9430 Stinchcombe, Thomas E. , Mauer, Ann M. , Hodgson, Lydia D. ... - - J Thorac Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9430
High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): Correlation with diagnostic features and treatment outcome (CALGB 9710) Stock, W. , Najib, K. , Moser, B. K. , Holowka, N. , Powell, B. L. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leuk Corr Sci - C9710 , CALGB-9665
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies Stock, Wendy , La, Mei , Sanford, Ben , Bloomfield, Clara D. ... - - Blood - 2008 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - CALGB-8811 , CALGB-9331 , CALGB-19802 , CALGB-8461 , CALGB-9111 , CALGB-9511
Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups Strauss, Gary M. , Herndon, James E. , Maddaus, Michael A. ... - - J Clin Oncol - 2008 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Respiratory - CALGB-9633
Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781 Tepper, Joel , Krasna, Mark J. , Niedzwiecki, Donna , Hollis, Donna ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - GI - C9781
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia Tomasson, Michael H. , Xiang, Zhifu , Walgren, Richard , Zhao, Yu ... - - Blood - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-9621 , CALGB-9665
Use of baseline quality of life (QOL) as compared with performance status (PS) as prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer (mCRC) Turja, J. , Grothey, A. , Sargent, D. , Szydlo, D. , Zhao, X. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N9741
Lymph node analysis in esophageal resection: American College of Surgeons Oncology Group Z0060 trial. Veeramachaneni, Nirmal K , Zoole, Jennifer B , Decker, Paul A ... - - Ann. Thorac. Surg. - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0060
Economic analysis of the Clinical Outcomes of Surgical Therapy (COST) trial comparing laparoscopically-assisted colectomy (LAC) with open colectomy (OC) for colon cancer. Weeks, J. , Nelson, H. , Romanus, D. , Long, K. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Health Outcome - INT-0146 , NCCTG-93-46-55 , CALGB-9396
Imatinib and Autologous Stem Cell Transplantation for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) – CALGB study 10001 Wetzler, M. , Stock, W. , Linker, C. ... - - Ann Hematol - 2008 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10001
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107 Wetzler, Meir , Donohue, Kathleen A. , Odenike, Olatoyosi M. ... - - Leuk. Lymphoma - 2008 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10107
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication Whitman, Susan P. , Hackanson, Björn , Liyanarachchi, Sandya ... - - Blood - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-20502 , CALGB-9665 , CALGB-9769
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications Whitman, Susan P. , Ruppert, Amy S. , Radmacher, Michael D. ... - - Blood - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leuk Corr Sci - CALGB-19808 , CALGB-20502 , CALGB-8461 , CALGB-9621 , CALGB-9665
Multi-center study of dose-adjusted epoch-r in untreated diffuse large b-cell lymphoma: CALGB 50103 Wilson, W. H. , Zelenetz, A. D. , Niedzwiecki, D. , Hurd, D. D. ... - - Ann. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50103
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group Witzig, Thomas E. , Geyer, Susan M. , Kurtin, Paul J. ... - - Leuk. Lymphoma - 2008 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N9981
